达格列净治疗2型糖尿病合并心血管疾病的快速卫生技术评估

潘慧敏; 王钰博; 陈迹; 单慧亭; 陈春燕; 杨建华

doi:10.6039/j.issn.1001-0408.2024.18.18

您当前的位置：

首页 >

文章列表页 >

达格列净治疗2型糖尿病合并心血管疾病的快速卫生技术评估

循证药学 | 更新时间：2024-09-25

- 达格列净治疗2型糖尿病合并心血管疾病的快速卫生技术评估
- Rapid health technology assessment of dapagliflozin in the treatment of type 2 diabetes mellitus combined with cardiovascular disease
- 中国药房 2024年35卷第18期页码：2293-2298
- 作者机构：
  
  1.新疆医科大学第一附属医院药学部，乌鲁木齐　830011
  2.新疆药物临床研究重点实验室，乌鲁木齐　830011
- 作者简介：
  
  药师，硕士。研究方向：药学流行病学、药物经济学。E-mail：1129694948@qq.com
  主任药师，教授，博士。研究方向：药学流行病学、药物经济学。E-mail：yjh-yft@163.com
- 基金信息：
  
  国家卫生健康委医学科技发展研究中心面上课题(WKZX2023CX210008);新疆维吾尔自治区重大科技专项课题(2022A03006-2);新疆维吾尔自治区药品临床综合评价项目(XJWJYZ202403)
- DOI：10.6039/j.issn.1001-0408.2024.18.18
  中图分类号： R977.1+5;R587.1
- 纸质出版日期：2024-09-30，
  
  收稿日期：2024-03-28，
  
  修回日期：2024-08-16，
- 稿件说明：
移动端阅览
潘慧敏,王钰博,陈迹等.达格列净治疗2型糖尿病合并心血管疾病的快速卫生技术评估 ^Δ[J].中国药房,2024,35(18):2293-2298.

PAN Huimin,WANG Yubo,CHEN Ji,et al.Rapid health technology assessment of dapagliflozin in the treatment of type 2 diabetes mellitus combined with cardiovascular disease[J].ZHONGGUO YAOFANG,2024,35(18):2293-2298.
潘慧敏,王钰博,陈迹等.达格列净治疗2型糖尿病合并心血管疾病的快速卫生技术评估 ^Δ[J].中国药房,2024,35(18):2293-2298. DOI： 10.6039/j.issn.1001-0408.2024.18.18.

PAN Huimin,WANG Yubo,CHEN Ji,et al.Rapid health technology assessment of dapagliflozin in the treatment of type 2 diabetes mellitus combined with cardiovascular disease[J].ZHONGGUO YAOFANG,2024,35(18):2293-2298. DOI： 10.6039/j.issn.1001-0408.2024.18.18.

摘要

目的

评价达格列净治疗2型糖尿病（T2DM）合并心血管疾病（CVD）的安全性、有效性及经济性，为临床治疗决策提供循证依据。

方法

检索PubMed、the Cochrane Library、Embase 、Web of Science、中国知网、万方数据、维普网、中国生物医学文献数据库以及国内外卫生技术评估（HTA）相关机构官方网站，收集达格列净治疗T2DM合并CVD的HTA报告、系统评价/Meta分析和药物经济学研究。资料提取、评价质量后，对纳入研究的结果进行描述性分析。

结果

共纳入文献13篇，其中系统评价/Meta分析10篇、药物经济学研究3篇。有效性方面，与安慰剂比较，达格列净可显著降低患者的糖化血红蛋白、体重、体重指数及血压水平，且未增加全因病死风险。安全性方面，达格列净未增加患者总体不良反应、主要心血管不良事件、心血管病死、心力衰竭住院、心肌梗死、脑卒中、骨折、肾功能减退的发生风险。经济性方面，英国及中国经济学研究认为，达格列净具有经济学优势；泰国经济学研究认为，该药不具有经济学优势。

结论

达格列净治疗T2DM合并CVD的有效性和安全性较好；经济性结论在不同国家存在差异，在我国当前医疗政策及药品价格背景下达格列净具有经济学优势。

Abstract

OBJECTIVE

To evaluate the safety， efficacy and economics of dapagliflozin in the treatment of type 2 diabetes mellitus （T2DM） combined with cardiovascular disease （CVD）， and provide an evidence-based basis for clinical treatment decisions.

METHODS

PubMed， the Cochrane Library， Embase， Web of Science， CNKI， Wanfang data， VIP， SinoMed and official websites of domestic and foreign health technology assessment （HTA） organizations were systematically searched. HTA reports， systematic evaluations/meta-analyses， and pharmacoeconomic studies of dapagliflozin in the treatment of T2DM combined with CVD were searched. After data extraction and quality assessment， the results of the included studies were analyzed descriptively.

RESULTS

A total of 13 papers were included， of which 10 were systematic evaluations/meta-analyses and 3 were pharmacoeconomic studies. In terms of efficacy， dapagliflozin significantly reduced patients’ glycosylated hemoglobin， body weight， body mass index and blood pressure levels compared with placebo， without increasing the risk of all-cause mortality； in terms of safety， dapagliflozin did not increase the risk of overall adverse events， major adverse cardiovascular events， cardiovascular death， hospitalization for heart failure， myocardial infarction， stroke， bone fracture and renal hypoplasia； in terms of economics， the UK and Chinese studies found an economic advantage for dapagliflozin， the Thai study did not.

CONCLUSIONS

Dagliflozin has better efficacy and safety in the treatment of T2DM combined with CVD， and its economic findings are still controversial in different countries， with economic advantages in the context of current Chinese healthcare policies and drug prices.

关键词

达格列净2型糖尿病心血管疾病快速卫生技术评估有效性安全性经济性

Keywords

type 2 diabetes mellituscardiovascular diseaserapid health technology assessmenteffectivenesssafetyeconomics

references

SUN H，SAEEDI P，KARURANGA S，et al. IDF diabetes atlas：global，regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract，2022，183：109119.

中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2022概要[J]. 中国循环杂志，2023，38（6）：583-612.

China Cardiovascular Health and Disease Report Writing Group. Report on cardiovascular health and diseases in China 2022：an updated summary[J]. Chin Circ J，2023，38（6）：583-612.

MOSENZON O，ALGUWAIHES A，LEON J L A，et al. CAPTURE：a multinational，cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries[J]. Cardiovasc Diabetol，2021，20（1）：154.

ZHOU X H，JI L N，RAN X W，et al. Prevalence of obesity and its influence on achievement of cardiometabolic therapeutic goals in Chinese type 2 diabetes patients：an analysis of the nationwide，cross-sectional 3B study[J]. PLoS One，2016，11（1）：e0144179.

COLE J B，FLOREZ J C. Genetics of diabetes mellitus and diabetes complications[J]. Nat Rev Nephrol，2020，16（7）：377-390.

LOKE Y K，KWOK C S，SINGH S. Comparative cardiovascular effects of thiazolidinediones：systematic review and meta-analysis of observational studies[J]. BMJ，2011，342：d1309.

WIVIOTT S D，RAZ I，BONACA M P，et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med，2019，380（4）：347-357.

KOSIBOROD M，CAVENDER M A，FU A Z，et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs：the CVD-REAL study（comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors）[J]. Circulation，2017，136（3）：249-259.

TORNYOS D，MEUER M，LUKÁCS R，et al. Cardio-vascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors，a network meta-analysis of randomized trials[J]. Front Cardiovasc Med，2022，9：1041200.

WU Q L，ZHENG T，LI S Z，et al. Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes：a meta-analysis of randomized controlled trials[J]. Diabetol Metab Syndr，2022，14（1）：41.

American Diabetes Association. 2： classification and diagnosis of diabetes：standards of medical care in diabetes：2018[J]. Diabetes Care，2018，41（Suppl. 1）：S13-S27.

中华医学会糖尿病学分会. 中国2型糖尿病防治指南：2020年版[J]. 中华糖尿病杂志，2021，13（4）：95.

Diabetes Branch，Chinese Medical Association. Guidelines for the prevention and treatment of type 2 diabetes mel-litus in China：2020 edition[J]. Chin J Diabetes Mellitus，2021，13（4）：95.

HUANG K Y，WANG Y，SUN S J，et al. Cost-effectiveness analysis of dapagliflozin plus standard treatment for patients with type 2 diabetes and high risk of cardiovascular disease in China[J]. Front Public Health，2022，10：936703.

唐惠林，门鹏，翟所迪. 药物快速卫生技术评估方法及应用[J]. 临床药物治疗杂志，2016，14（2）：1-4.

TANG H L，MEN P，ZHAI S D. Introducing and explo-ring the method of rapid review on drugs[J]. Clin Med J，2016，14（2）：1-4.

嵇承栋，朱琳懿，万悦竹，等. 国际卫生技术评估机构协作网卫生技术评估报告清单解读[J]. 中国循证医学杂志，2016，16（3）：369-372.

JI C D，ZHU L Y，WAN Y Z，et al. An introduction of reporting checklist of health technology assessment deve-loped by the International Network of Agencies for Health Technology Assessment[J]. Chin J Evid Based Med，2016，16（3）：369-372.

张方圆，沈傲梅，曾宪涛，等. 系统评价方法学质量评价工具AMSTAR 2解读[J]. 中国循证心血管医学杂志，2018，10（1）：14-18.

ZHANG F Y，SHEN A M，ZENG X T，et al. An introduction to AMSTAR 2：a critical appraisal tool for systematic reviews[J]. Chin J Evid Based Cardiovasc Med，2018，10（1）：14-18.

HUSEREAU D，DRUMMOND M，AUGUSTOVSKI F，et al. Consolidated health economic evaluation reporting standards （CHEERS） 2022 explanation and elaboration： a report of the ISPOR CHEERS Ⅱ good practices task force[J]. Value Health，2022，25（1）：10-31.

万力. 达格列净治疗糖尿病合并心力衰竭疗效的Meta分析[D]. 重庆：重庆医科大学，2022.

WAN L. Meta-analysis of dapagliflozin’s therapeutic effect on diabetes complicated with heart failure[D].Chongqing：Chongqing Medical University，2022.

田丽，王琼英，孙润民，等. SGLT2i对2型糖尿病合并高血压患者24 h动态血压影响的荟萃分析[J]. 中华心血管病杂志，2021，49（10）：1000-1011.

TIAN L，WANG Q Y，SUN R M，et al. Effects of SGLT2i on 24-hour ambulatory blood pressure in patients with type 2 diabetes complicating hypertension：a meta-analysis[J]. Chin J Cardiol，2021，49（10）：1000-1011.

TÄGER T，FRANKENSTEIN L，ATAR D，et al. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure：a systematic review and head-to-head comparative efficacy network meta-analysis[J]. Clin Res Cardiol，2022，111（4）：428-439.

LOU Y K，YU Y，DUAN J C，et al. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus：a meta-analysis of randomized controlled trials[J]. Ther Adv Chronic Dis，2020，11：2040622320961599.

GHOSAL S，SINHA B. Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes：a frequentist and Bayesian network meta-analysis-based scoring[J]. Front Endocrinol，2023，14：1168755.

DEEROCHANAWONG C，VAREESANGTHIP K，PIYAYOTAI D，et al. Cost-utility analysis of dapagliflozin as an add-on to standard treatment for patients with type 2 diabetes and high risk of cardiovascular disease in Thailand[J]. Diabetes Ther，2021，12（7）：1947-1963.

MCEWAN P，MORGAN A R，BOYCE R，et al. The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus：an economic evaluation using data from the DECLARE-TIMI 58 trial[J]. Diabetes Obes Metab，2021，23（4）：1020-1029.

SONESSON C，JOHANSSON P A，JOHNSSON E，et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories：a meta-analysis[J]. Cardiovasc Diabetol，2016，15：37.

ODUTAYO A，DA COSTA B R，PEREIRA T V，et al. Sodium-glucose cotransporter 2 inhibitors，all-cause mortality，and cardiovascular outcomes in adults with type 2 diabetes：a Bayesian meta-analysis and meta-regression[J]. J Am Heart Assoc，2021，10（18）：e019918.

CAPARROTTA T M，GREENHALGH A M，OSINSKI K，et al. Sodium-glucose co-transporter 2 inhibitors（SGLT2i）exposure and outcomes in type 2 diabetes：a systematic review of population-based observational studies[J]. Diabetes Ther，2021，12（4）：991-1028.

PERSSON F，NYSTRÖM T，JØRGENSEN M E，et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes（CVD-REAL Nordic）when compared with dipeptidyl peptidase-4 inhibitor therapy：a multinational observational study[J]. Diabetes Obes Metab，2018，20（2）：344-351.

江耀辉，王喆，郑汝杰，等. 达格列净对冠心病合并2型糖尿病患者临床结局的影响[J]. 中国循环杂志，2022，37（3）：250-255.

JIANG Y H，WANG Z，ZHENG R J，et al. Impact of dapagliflozin on the clinical outcomes of patients with coronary artery disease and type 2 diabetes mellitus[J]. Chin Circ J，2022，37（3）：250-255.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

洛拉替尼治疗非小细胞肺癌的快速卫生技术评估

玛巴洛沙韦治疗流行性感冒的快速卫生技术评估

利那洛肽治疗便秘型肠易激综合征的快速卫生技术评估

两性霉素B联合泊沙康唑治疗艾滋病合并隐球菌性脑膜炎的有效性及安全性

卡瑞利珠单抗联合培美曲塞和奈达铂治疗EGFR/ALK野生型晚期非鳞状NSCLC的临床观察